The present method relates to methods of expanding or increasing stem cell production obtained from donor samples. The methods preferably including the steps of harvesting cells from minimally manipulated tissue using multiply harvesting cycles to increase the number of obtained stem cells.

The present invention relates to a method for promoting growth of gas-fermented microorganisms, comprising the following steps: S1. ultrasonically blending a surfactant and a culture medium, then adding a fluorine-containing alkyl compound to a mixture, and ultrasonically processing the mixture to obtain a perfluorocarbon nanoemulsion; S2. inoculating a bacterial suspension into the perfluorocarbon nanoemulsion, and introducing simultaneously a mixed gas to obtain a precursor; S3. cultivating the precursor in a shaker, wherein the precursor has a diameter of bubbles of 2.0-4.2 mm, and the bubbles have the total volume of less than 40 ml. Under these conditions, the microorganisms have a high utilization rate of the gas, can grow and metabolize more quickly, and can obtain bacteria and products more quickly. Compared with a traditional culture system, addition of a mass transfer material can promote gas mass transfer. Therefore, the gas consumption is small, and the cost is low.

The present inventions provide methods to control the heterogeneity of Fc-containing proteins, such as antibodies produced in cell culture, particularly mammalian cell culture by controlling culture pCO.sub.2, as well as products produced by these methods. Among other things, the inventions provide for lowering the percentage of acidic charge variants in antibody products. Proteins that comprise Fc moieties include but are not limited to Fc-containing proteins, such as antibodies and antibody derivatives, and fragments of both.

A method for producing astaxanthin, comprising: (a) acquiring vegetative cells of astaxanthin-producing Haematococcus pluvialis; (b) heterotrophically culturing the vegetative cells of astaxanthin-producing Haematococcus pluvialis in a nutrient-poor culture medium containing an organic carbon source and under a no-light condition, to obtain spore cells; and (c) harvesting the spore cells and/or astaxanthin, and optionally purifying the astaxanthin. Also provided is a culture medium used in the described method.

The present disclosure relates generally to therapeutic agents that may be useful as modulators of Integrated Stress Response (ISR) pathway.

This application provides methods, compositions, and kits for use blood group determination and the preparation of improved red blood cell containing reagents for use in blood typing of blood prior to its use in transfusion medicine.

The invention relates to a new process for manufacturing in vitro antigen-specific T lymphocytes (CellTrAg), marked with intracellular dye and expanded in the presence of monocytes loaded with the antigen and subsequently sorted based on the low intensity of intracellular dye where the low intensity of fluorescence is a marker of antigen-specificity in that a loss of fluorescence correlated with the intensity of proliferation. The antigen specificity is assessed in functional tests in which antigen-specific lymphocytes sorted on the basis of low fluorescence are more active than non-specific lymphocytes with high fluorescence during sort; activity is defined in the case of regulatory T lymphocytes as inhibition of effector lymphocyte function and in the case of T effector lymphocytes as enhancing the characteristics of these cells such as proliferation, production of cytokines and cytotoxic factors.

The invention provides culture platforms, cell media, and methods of differentiating pluriptent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, and NK cells.

A method is provided for producing a live cartilaginous material useful for implantation into a patient. A method of treating a patient comprising implanting a cartilaginous material prepared according to the provided method in an anatomical site in a patient also is provided.

The present application relates to cells having high adaptability under hypoxic conditions and to a preparation method therefor. Particularly, the present disclosure provides cells having high adaptability under hypoxic conditions, the cells including at least one engineered gene having an indel within a wild-type gene selected from the group consisting of HIF1AN, HIF3A, PHD2, TLR4 and PAI1. In addition, the present disclosure provides, as a method for preparing cells having high adaptability under hypoxic conditions, a gene editing method including introducing a CRISPR/Cas9 system into cells.